Too often, recruiters are more clear on what a position will “do” rather than what it will “achieve”.Outlining tasks and responsibilities takes priority over goals and impact.But to attract top talent, you need to define and explain what success looks…
HOME > BUSINESS
BUSINESS
- Takeda’s R&D Organization Rejig Making Steady Headway as a Whole
February 2, 2017
- New Firm for Nesp Biosimilar Will Broaden Options: Kyowa Kirin President
February 2, 2017
- EA Pharma Seeks Japan Approval of Constipation Med
February 2, 2017
- Chugai Logs Positive Sales in Japan, but Earnings Falter
February 2, 2017
- Gilead to Introduce Blister-Pack Harvoni by Early March
February 2, 2017
- Over 80% of 5-Year-Olds Eligible for Supplemental Dose of Pneumococcal Vaccine: Pfizer Survey
February 2, 2017
- Daiichi Sankyo Taps EVP Manabe as Next President
February 1, 2017
- KHK7580 Non-Inferior to Regpara in Japan Study: Kyowa Kirin
February 1, 2017
- Kyowa Kirin Sets Up New Firm for Nesp Authorized Biosimilar
February 1, 2017
- Daiichi Sankyo Sees High Odds of Success for CAR T-Cell Development: Exec
February 1, 2017
- Kyowa Kirin’s 2016 Sales, Profits Slip on Stronger Yen, Higher R&D Costs
February 1, 2017
- Kyowa Kirin, NCC to Collaborate on Cancer Meds, Biomarkers
February 1, 2017
- Takeda Obtains Japan Rights to Exelixis’ Cancer Drug
February 1, 2017
- Astellas Gets Rights to US Biotech’s Ruptured Eardrum Med
February 1, 2017
- Major Products Face Impending Listing of Generics, though Patents Remain for Some
February 1, 2017
- Biogen to Keep Its Focus on High Unmet Needs, Win-Win Partnerships: CEO
January 31, 2017
- Latuda OK’ed in US for Adolescent Schizophrenia
January 31, 2017
- Mochida Filed Enbrel Biosimilar in Japan in October-December
January 31, 2017
- Linzess Delivers Positive Japan PIII Data in Chronic Constipation: Astellas
January 31, 2017
- Nippon Chemiphar, Nagase Medicals Win Elplat Patent Suit
January 30, 2017
ページ
Pharmaceutical companies are giving high marks to Japan’s drug pricing reform for FY2024. According to a survey conducted by Jiho, 51% of all respondents expressed a positive opinion of the reform, saying that they were “somewhat satisfied” with it. The…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…